

P1 1189202

REC'D 08 JUL 2004

WIPO

PCT

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

July 01, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/465,281

FILING DATE: April 21, 2003

RELATED PCT APPLICATION NUMBER: PCT/US04/09667

By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS



E. Bornett
E. BORNETT
Certifying Officer

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

04/21/03

JC912 U.S. PTO

04-25-03

60-465281

A11Kov

PTO/SB/16 (10-01)


U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No. EV 336102945 US

INVENTOR(S)					
Given Name (first and middle [if any])		Family Name or Surname		Residence (City and either State or Foreign Country)	
Mark		Matteucci		Portola Valley, CA	
Photon		Rao		Millbrae, CA	
<input type="checkbox"/> Additional inventors are being named on the separately numbered sheets attached hereto					
TITLE OF THE INVENTION (500 characters max)					
COMPOSITIONS AND METHODS FOR TREATING CANCER					
Direct all correspondence to: CORRESPONDENCE ADDRESS					
<input checked="" type="checkbox"/> Customer Number				 20350 PATENT TRADEMARK OFFICE	
OR		Type Customer Number here			
<input type="checkbox"/> Firm or Individual Name					
Address					
Address					
City		State		ZIP	
Country		Telephone		Fax	
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/> Specification Number of Pages		35		<input type="checkbox"/> CD(s), Number	
<input type="checkbox"/> Drawing(s) Number of Sheets				<input checked="" type="checkbox"/> Other (specify) Fee Transmittal	
<input checked="" type="checkbox"/> Application Data Sheet. See 37 CFR 1.76					
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT					
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.		FILING FEE AMOUNT (\$)			
<input type="checkbox"/> A check or money order is enclosed to cover the filing fees					
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number:		20-1430		80	
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input checked="" type="checkbox"/> No.					
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are:					

Respectfully submitted,
SIGNATURE

Date 4/23/03

TYPED or PRINTED NAME William Schmonsees

REGISTRATION NO. 31,796
(if appropriate)

TELEPHONE 650-326-2400

Docket Number: 021305-001500US

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C., 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Provisional Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. PA 3300815 v1

JC912 U.S. PTO

60/465281

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Approved for use through 04/30/2003. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

FEE TRANSMITTAL for FY 2003

Effective 01/01/2003. Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 80

Application Number To Be Assigned

Filing Date April 23, 2003

First Named Inventor Matteucci, Mark

Examiner Name To Be Assigned

Art Unit To Be Assigned

Attorney Docket No. 021305-001500US

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ MoneyOrder ☐ Other ☐ None

☒ Deposit Account:

Deposit
Account
Number

20-1430

Deposit
Account
Name

Townsend and Townsend and Crew LLP

The Commissioner is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments
☒ Charge any additional fee(s) during the pendency of this application
☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity	Small Entity	Fee Code	Fee (\$)	Fee Description	Fee Paid
		1001	750	Utility filing fee	
		1002	330	Design filing fee	
		1003	520	Plant filing fee	
		1004	750	Reissue filing fee	
		1005	160	Provisional filing fee	
		2001	375		
		2002	165		
		2003	260		
		2004	375		
		2005	80		

SUBTOTAL (1)

(\$80)

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	Extra Claims	Fees from below	Fee Paid
Independent Claims			
Multiple Dependent			

Large Entity	Small Entity	Fee Code	Fee (\$)	Fee Description	Fee Paid
		1202	18	Claims in excess of 20	
		1201	84	Independent claims in excess of 3	
		1203	280	Multiple dependent claim, if not paid	
		1204	84	** Reissue independent claims over original patent	
		1205	18	** Reissue claims in excess of 20 and over original patent	
		2202	9		
		2201	42		
		2203	140		
		2204	42		
		2205	9		

SUBTOTAL (2)

(\$)

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity	Small Entity	Fee Code	Fee (\$)	Fee Description	Fee Paid
		1051	130	Surcharge - late filing fee or oath	
		1052	50	Surcharge - late provisional filing fee or cover sheet	
		1053	130	Non-English specification	
		1812	2,520	For filing a request for reexamination	
		1804	920*	Requesting publication of SIR prior to Examiner action	
		1805	1,840*	Requesting publication of SIR after Examiner action	
		1251	110	Extension for reply within first month	
		1252	410	Extension for reply within second month	
		1253	930	Extension for reply within third month	
		1254	1,450	Extension for reply within fourth month	
		1255	1,970	Extension for reply within fifth month	
		1401	320	Notice of Appeal	
		1402	320	Filing a brief in support of an appeal	
		1403	280	Request for oral hearing	
		1451	1,510	Petition to institute a public use proceeding	
		1452	110	Petition to revive - unavoidable	
		1453	1,300	Petition to revive - unintentional	
		1501	1,300	Utility issue fee (or reissue)	
		1502	470	Design issue fee	
		1503	630	Plant issue fee	
		1460	130	Petitions to the Commissioner	
		1807	50	Petitions related to provisional applications	
		1806	180	Submission of Information Disclosure Stmt	
		8021	40	Recording each patent assignment per property (times number of properties)	
		1809	750	Filing a submission after final rejection (37 CFR § 1.129(a))	
		1810	750	For each additional invention to be examined (37 CFR § 1.129(b))	
		1801	750	Request for Continued Examination (RCE)	
		1802	900	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid SUBTOTAL (3)

(\$)

SUBMITTED BY

Name (Print/Type)

William Schmonsees

Registration No. (Attorney/Agent)

31,788

Telephone

650-326-2400

Signature



Date

April 23, 2003

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. PA 3300813 v1

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-788-9199) and select option 2.

Application Data Sheet

Application Information

Application number::	To Be Assigned
Filing Date::	04/23/03
Application Type::	Provisional
Subject Matter::	Utility
Title::	Compositions and Methods for Treating Cancer
Attorney Docket Number::	021305-001500US
Request for Early Publication::	No
Request for Non-Publication::	No
Small Entity?::	Yes
Petition included?::	No
Secrecy Order in Parent Appl.::	No

Applicant Information

Applicant Authority Type::	Inventor
Primary Citizenship Country::	US
Status::	Full Capacity
Given Name::	Mark
Family Name::	Matteucci
City of Residence::	Portola Valley
State or Province of Residence::	CA
Country of Residence::	US
Street of Mailing Address::	135 Fawn Lane
City of Mailing Address::	Portola Valley
State or Province of mailing address::	CA
Country of mailing address::	US
Postal or Zip Code of mailing address::	94028

Applicant Authority Type:: Inventor
Primary Citizenship Country:: India
Status:: Full Capacity
Given Name:: Photon
Family Name:: Rao
City of Residence:: Millbrae
State or Province of Residence:: CA
Country of Residence:: US
Street of Mailing Address:: #4 485 Lincoln Circle
City of Mailing Address:: Millbrae
State or Province of mailing address:: CA
Country of mailing address:: US
Postal or Zip Code of mailing address:: 94030

Correspondence Information

Correspondence Customer Number:: 20350

Representative Information

Representative Customer Number:: 20350

Assignee Information

Assignee Name:: Threshold Pharmaceutical, Inc.
Street of mailing address:: 951 Gateway Blvd, Suite 3A
City of mailing address:: South San Francisco
State or Province of mailing address:: CA
Country of mailing address:: US
Postal or Zip Code of mailing address:: 94080

Attorney Docket No.: 021305-001500US
Express Mail No.: EV 336102945 US

PROVISIONAL
PATENT APPLICATION

Compositions and Methods for Treating Cancer

Inventors: Mark Matteucci, citizen of the United States, residing at 135 Fawn Lane,
Portola Valley, CA 94028; and

Photon Rao, a citizen of India residing at #4 485 Lincoln Circle, Millbrae, CA
94030

Assignee: Threshold Pharmaceuticals, Inc.
951 Gateway Blvd., Suite 3A
South San Francisco, CA 94080

Entity: Small business concern

As Filed April 23, 2003

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 925-472-5000

Compositions and Methods for Treating Cancer

FIELD OF THE INVENTION

[0001] The present invention provides methods, compounds, and compositions useful in
5 the treatment of cancer and so relates to the fields of chemistry, medicinal chemistry,
pharmacology, and medicine.

BACKGROUND OF THE INVENTION

[0002] The term "cancer" generally refers to one of a group of more than 100 diseases
10 caused by the uncontrolled growth and spread of abnormal cells that can take the form of
solid tumors, lymphomas, and non-solid cancers such as leukemia. Unlike normal cells,
which reproduce until maturation is attained and then only as necessary for replacement,
cancer cells grow and divide endlessly, crowding out nearby cells and eventually spreading to
15 other parts of the body, unless their progression is stopped. Once cancer cells metastasize by
leaving a tumor, they will travel through the bloodstream or lymphatic system to other parts
of the body, where the cells begin multiplying and developing into new tumors. This sort of
tumor progression makes cancer dangerously fatal. Although there have been great
improvements in diagnosis, general patient care, surgical techniques, and local and systemic
adjuvant therapies, most deaths from cancer are still due to metastases and other cancers that
20 are resistant to conventional therapies including radiation and chemotherapy.

[0003] Radiation therapy is typically only effective for cancer treatment at early and
middle stages of cancer, when cancer is localized, and not effective for late stage disease with
metastasis. Chemotherapy can be effective at all stages of the disease, but there can be severe
side effects, e.g. vomiting, low white blood cells, loss of hair, loss of weight and other toxic
25 effects, to radiation therapy and chemotherapy. Because of such severe side effects, many
cancer patients do not or cannot successfully complete a chemotherapy treatment regimen.
The side effects of radiation and anticancer drugs can be viewed as resulting from poor target
specificity. Anticancer drugs, typically administered intravenously or more rarely orally,
circulate through most normal tissues of patients as well as the target tumors. If the drug is
30 toxic to a normal cell, then this circulation will result in the death of normal cells, leading to
side effects, and the more toxic the drug to normal cells, the more serious the side effects.

Due to these and other problems, some highly cytotoxic chemotherapeutic agents, agents with nanomolar or sub-nanomolar IC₅₀ values against cancer cells, have not been successfully developed into approved drugs.

[0004] Prodrugs have been investigated as a means to lower the unwanted toxicity or some other negative attribute of a drug without loss of efficacy. A prodrug is a drug that has been chemically modified to render it inactive but that, subsequent to administration, is metabolized or otherwise converted to the active form of the drug in the body. For example, in an effort to improve drug targeting, prodrugs have been developed that are activated under hypoxic conditions. Hypoxia creates a bioreductive environment, and certain anti-cancer agents have been converted into prodrugs that can be activated in such environments. See the reviews by Naylor *et al.*, May 2001, *Mini. Rev. Med. 1*(1):17-29, and Denny, 2001, *Eur. J. Med Chem. 36*: 577-595. "Hypoxia" is a condition of low oxygen levels; most solid tumors larger than about 1 mm in diameter contain hypoxic regions (see the references Coleman, 1988, *J. Nat. Canc. Inst. 80*: 310; and Vaupel *et al.*, *Cancer Res. 49*: 6449).

[0005] As a tumor grows, it requires a blood supply and thus the growth of new vasculature. The new vasculature that supports tumor growth is often highly unordered, leaving significant portions of the tumor under-vascularized and subject to intermittent vascular blockage. The vascular architecture of the tumor can contribute significantly to the cancer's ability to survive drug therapy in at least two different ways. First, if the drug must reach the cancer through the bloodstream, then not as much drug will reach the under-vascularized, hypoxic areas of the tumor. Second, to the extent the drug requires oxygen to be effective, then the drug will be less effective in the hypoxic regions of the tumor.

[0006] Conversely, however, the hypoxic environment is conducive to reductive events that can be used to generate reduced derivatives of a variety of chemical groups (see the reference Workman *et al.*, 1993, *Cancer and Metast. Rev. 12*: 73-82), and bioreductive prodrug compounds have been developed to exploit such environments. These prodrugs include the antibiotics Mitomycin C (MMC) and Porfiromycin (POR), N-oxides such as Tirapazamine (TRZ; see the reference Zeeman *et al.*, 1986, *Inst. J. Radiot. Oncol. Biol. Phys. 12*: 1239), quinones such as the indoloquinone E09 (see the reference Bailey *et al.*, 1992, *Int. J. Radiot. Oncol. Biol. Phys. 22*: 649), cyclopropamitosenes (EP-A-0868137), and a tertiary amine-N-oxide analogue of Mitoxantrone (AQ4N) that is activated by cytochrome P450 3A4

(see the references Patterson, 1993, *Cancer Metast. Rev.* 12: 119; and Patterson, 1994, *Biochem. Pharm. Oncol. Res.* 6: 533).

5 [0007] Other bioreductively activated prodrug compounds include the nitroimidazole derivatives that have been reported to be useful in cancer radiotherapy as radio-sensitizing agents (see the patent publications EP312858 and WO91/11440) and potentiators of chemotherapeutic agents (see U.S. Patent No. 4,921,963). Nitroimidazole has also been conjugated to the anti-cancer agent PARP 5-bromoisoquinolinone (see the reference Parveen et al., Jul. 1999, *Bioorg. Med. Chem. Lett.*, 9:2031-36). The nitroimidazole moiety itself is, however, somewhat cytotoxic to normal cells, because it undergoes redox cycling and
10 generates superoxides under oxygenated conditions.

[0008] Thus, there remains a need to provide drugs to treat cancer. Such drugs would be especially beneficial if they targeted cancer cells more effectively than current drugs and had fewer, less serious side effects. The present invention helps meet this need.

15

SUMMARY OF THE INVENTION

[0009] The present invention provides compounds, compositions, and methods for treating cancer.

20 [0010] In one aspect, the present invention provides methods for treating cancer in a subject, comprising administering to the subject an effective amount of a hypoxia-activated prodrug of the invention, alone or in combination with another anti-cancer agent or therapeutic treatment, including surgery and radiation.

[0011] In another aspect, the present invention provides compounds that are hypoxia-activated prodrugs having a structure defined by the formula: Hyp-L-N, wherein Hyp is a hypoxic activator; L is a bond or a linking group or linker; and N is an anti-neoplastic agent.

25 [0012] In one embodiment, the hypoxic activator is selected from the group consisting of an electron deficient nitrobenzene, an electron deficient nitrobenzoic acid amide, a nitroazole, a nitroimidazole, a nitrothiophene, a nitrothiazole, a nitrooxazole, and a nitrofuran. The prodrug can comprise one, two, or more such hypoxic activator moieties. In one embodiment, the bond or linker is an ester, ether, acetal or carbamate.

[0013] In one embodiment, the anti-neoplastic agent N is selected from the group consisting of cytotoxic agents having an IC_{50} less than 100 microM, and optionally less than 1 microM, as defined by the NCI screening assay as an LC_{50} after a 24 hr drug treatment of a sensitive cell line. In some embodiments, the cytotoxic agent has an IC_{50} less than 10 nanomolar. In one embodiment, N is doxorubicin or, when cleaved from the prodrug conjugate in the body, generates a doxorubicin derivative having an IC_{50} in the low nanomolar range. In one embodiment, N is selected from the group consisting of maytansines, enediyenes, discodermolides, epothilones, taxanes, calicheamicins, and tedanolides. In another embodiment, N is selected from the group consisting of etoposide, vinblastine, vincristine, topotecan, cyclophosphamide, 5-fluorouracil, AQ4N, and hydroxyurea.

[0014] In a third aspect, the present invention provides methods for synthesizing the prodrugs of the invention and compounds useful as intermediates in such synthetic methods.

[0015] In a fourth aspect, the present invention provides pharmaceutical formulations of the prodrugs of the invention.

[0016] These and other aspects and embodiments of the invention are described in more detail in the detailed description and claims that follow.

DETAILED DESCRIPTION OF THE INVENTION

[0017] To facilitate an understanding of the invention, the following definitions are provided, and unless defined otherwise, all technical and scientific terms used herein have the meanings ascribed to them by those of skill in the fields to which this invention belongs.

[0018] As used herein, "a" or "an" means "at least one" or "one or more."

[0019] As used herein, an "anti-neoplastic agent", "anti-tumor agent", or "anti-cancer agent", refers to any agent used in the treatment of cancer. Such agents can be used alone or in combination with other compounds and can alleviate, reduce, ameliorate, prevent, or place or maintain in a state of remission of clinical symptoms or diagnostic markers associated with neoplasm, tumor or cancer. Anti-neoplastic agents include, but are not limited to, anti-angiogenic agents, alkylating agents, antimetabolite, certain natural products, platinum coordination complexes, anthracenediones, substituted ureas, methylhydrazine derivatives, adrenocortical suppressants, certain hormones and antagonists, anti-cancer polysaccharides and certain herb or other plant extracts.

[0020] As used herein, an "anti-neoplastic treatment", "cancer therapy", or "cancer treatment" refers to any treatment designed to treat a neoplasm, tumor, or cancer by reducing the number of or growth of cancer cells in the body, typically by killing or halting the growth and division of cancer cells.

5 [0021] As used herein, a "bioreductive compound" refers to a compound that donates electrons in an oxidation-reduction reaction.

[0022] As used herein, "cancer" refers to a disease caused by a malignant tumor.

[0023] As used herein, "malignant" refers to cells that have the capacity of metastasis, with loss of both growth and positional control.

10 [0024] As used herein, "neoplasm" (neoplasia) or "tumor" refers to abnormal new cell or tissue growth, which may be benign or malignant.

[0025] As used herein, a "prodrug" is a compound that, after administration, is metabolized or otherwise converted to an active or more active form with respect to at least one property. To produce a prodrug, a pharmaceutically active compound can be modified chemically to
15 render it less active or inactive, but the chemical modification is such that an active form of the compound is generated by metabolic or other biological processes. A prodrug may have, relative to the drug, altered metabolic stability or transport characteristics, fewer side effects or lower toxicity, or improved flavor, for example (see the reference Nogrady, 1985, *Medicinal Chemistry A Biochemical Approach*, Oxford University Press, New York, pages
20 388-392). Prodrugs can also be prepared using compounds that are not drugs.

[0026] With these definitions, one can better appreciate the various aspects and embodiments of the invention described herein.

[0027] In one aspect, the present invention provides methods for treating cancer in a subject, such as a human or other mammal, said method comprising administering to the
25 subject a therapeutically effective amount of a hypoxia-activated prodrug of the invention, alone or in combination with one or more additional anti-cancer agents or anti-cancer treatments, including but not limited to surgery and radiation.

[0028] In another aspect, the present invention provides hypoxia-activated prodrugs having the formula: Hyp-L-N, wherein Hyp is a hypoxic activator; L is a bond or a linker;
30 and N is an anti-neoplastic agent. Those of skill in the art will appreciate that the anti-

neoplastic agent that is linked to the hypoxic moiety to form the prodrug can be different from the drug that is released from the prodrug upon activation. This aspect of the invention is illustrated in the Examples below, one of which shows that a prodrug of the invention can be synthesized by linking doxorubicin to a hypoxia-activated moiety of the invention to form a prodrug that releases an iminium-containing doxorubicin derivative that is far more toxic than doxorubicin. Thus, while the anti-neoplastic agent N in the formula above can sometimes be the same as the agent used in the synthesis of the prodrug, that term more importantly refers to the anti-neoplastic agent that is released from the prodrug.

[0029] The prodrugs of the invention, relative to the drugs to which they are converted *in vivo*, are much less (at least ten and up to one million-fold less) toxic. The reduced toxicity results from a modification at the site of attachment of the linker L (as in the case where activation of the prodrug releases the same cytotoxic agent that was used in the synthesis of the drug) or from the generation of a moiety required for toxicity by removal of the hypoxic moiety Hyp. In either event, the prodrugs of the invention are converted into the corresponding toxic drug in hypoxic tissues by virtue of the activation of the hypoxic activator moiety, resulting in its removal and the concomitant release or generation of the anti-neoplastic agent.

[0030] In one embodiment, the hypoxic activator moiety Hyp is selected from the group consisting of an electron deficient nitrobenzene, an electron deficient nitrobenzoic acid amide, a nitroazole, a nitroimidazole, a nitrothiophene, a nitrothiazole, a nitrooxazole, and a nitrofurane. The prodrug can comprise one, two, or more such hypoxic activator moieties, which may be the same or different. Preferred hypoxic activators of the invention include nitroimidazoles. Prodrugs containing nitroimidazoles can be used to "mask" (or upon activation, release) an aldehyde, amino, or hydroxyl group of a cytotoxic agent, groups often required for potent toxicity of a cytotoxic agent.

[0031] Nitroimidazoles have been used to form prodrugs of only two putative anti-cancer agents, a PARP inhibitor (see the reference Parveen *et al.*, 1999, *Bioorganic and Medicinal Letters* 9: 2031- 2036) and a nitrogen mustard, which was activated, not released, by the nitroimidazole (see the reference Lee *et al.*, 1998, *Bioorganic and Medicinal Letters* 8: 1741- 1744). The PARP inhibitor was shown to be released chemically, but no cell culture data was provided. The nitrogen mustard was shown to be active in cell culture data, and the

selectivity between normoxic and hypoxic toxicity, while not accurately measured, was stated as greater than 7 fold in cells with normal DNA repair mechanisms.

5 [0032] The prodrugs of the present invention differ from such known prodrugs either in the nature of the anti-neoplastic agent released, the better side effect profile, the presence of more than one hypoxia-activated moiety, or some combination of these attributes. These advantages of the prodrug compounds of the present invention can be better appreciated with an understanding of the pharmacokinetics of hypoxia-activated prodrugs generally and those of the invention particularly.

10 [0033] Nitroimidazole is, in the absence of oxygen, converted to a free radical containing moiety by a cytochrome P450 reductase. If the nitroimidazole is appropriately covalently bound to another moiety, further reduction of the free radical form of nitroimidazole can lead to release of that moiety. However, in the presence of oxygen, the free radical reacts with oxygen to form superoxide and the parent nitroimidazole. Superoxide is a cytotoxin, so the production of superoxide in normoxic tissues is believed to lead to unwanted side effects. The
15 prodrugs of the invention that release "super toxins" can be used in much lower doses than the nitroimidazole prodrugs heretofore known. These lower doses lead, in turn, to lower production of superoxide in normoxic tissue.

[0034] Certain nitroimidazole-containing prodrugs can also be activated regardless of the oxygen tension by DT diaphorase, which can lead to activation in normoxic cells, thus
20 contributing to unwanted side effects. Should this normoxic activation pathway create significant side effects with a particular prodrug of the invention, however, one can select another prodrug of the invention that contains more than one hypoxia-activated moiety to reduce or eliminate such side effects.

[0035] The prodrugs provided by the present invention are compounds that exhibit greater
25 efficacy and fewer side effects than prior art compounds. For example, certain preferred prodrugs of the invention are conjugated to, or are activated by hypoxic conditions to release, very powerful cytotoxic agents, "super toxins" with IC_{50} values of less than 100 nM against a majority of the cancer cell lines in the NCI tumor cell line panel. Even though the compounds of the invention still generate the superoxide that causes unwanted side effects, those side
30 effects are greatly reduced, because, on a molar basis, much less compound has to be given due to the highly cytotoxic nature of the anti-cancer agent released by the prodrug.

[0036] The prodrugs of the invention can, however, encompass a wide variety of anti-neoplastic agents. In one embodiment, the anti-neoplastic agent (N in the formula above) is selected from the group consisting of cytotoxic agents having an IC_{50} less than 1 microM, optionally less than 100 nanoM. In some embodiments, the IC_{50} of the cytotoxin released from the prodrug of the invention is less than 100 picomolar. In one embodiment, N is doxorubicin or, when cleaved from the prodrug conjugate in the body, generates a doxorubicin derivative having an IC_{50} in the low picomolar range, such as an iminium form of doxorubicin. In one embodiment, N is selected from the group consisting of maytansines, enediyenes, discodermolides, epothilones, taxanes, calicheamicins, and tedanolides. In another embodiment, N is selected from the group consisting of etoposide, vinblastine, vincristine, camptothecin, topotecan, cyclophosphamide, 5-fluorouracil, AQ4N, and hydroxyurea.

[0037] Other illustrative anti-neoplastic agents that can be incorporated in or released from the prodrugs of the invention include but are not limited to bleomycins, calicheamicins, colchicine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, discodermolides, doxorubicin and doxorubicin-like compounds such as epirubicin and derivatives, enediyenes, epothilones, etoposide, fludarabine, 5-fluorouracil or prodrugs thereof such as Xeloda marketed by Roche, hydroxyurea, hydroxyureapentostatin, maytansines, 6-mercaptopurine, methotrexate, mitomycin, mitoxantrone, platinum-containing agents including but not limited to carboplatin and cisplatin, prednisone, procarbazine, taxanes including but not limited to docetaxel and paclitaxel, tedanolides, teniposide, 6-thioguanine, topotecan, and vinca alkaloids including but not limited to vinblastine and vincristine.

[0038] Regardless of the anti-neoplastic agent selected for incorporation in or release by the prodrug, the linker and hypoxic activator moiety are attached to the agent in a manner that effectively masks or reduces its cytotoxic activity. This masking effect can vary and will of course depend on the cytotoxic activity of the anti-neoplastic agent to be released but will minimally be 10 fold or more, including up to one million fold or more, but typically 100 to 10,000-fold. As one example, for an anti-neoplastic agent with an IC_{50} of 1 nM, the corresponding IC_{50} of the prodrug can be 1 microM or greater. Thus, the prodrugs of the invention include prodrugs of any chemotherapeutic agent that can be linked to a hypoxia-activated moiety in a manner that yields a prodrug that is at least 10-fold to 1,000,000-fold,

typically 100 to 10,000-fold, less active as a cytotoxic agent than the drug that is released from the prodrug under hypoxic conditions.

[0039] In addition to contributing to the masking effect and to reducing the cytotoxic activity of the prodrug, the linker or some portion thereof must be capable of being released
5 upon hypoxic activation in a manner that generates the cytotoxic agent from the prodrug. For the preferred hypoxic moieties of the invention, the preferred linker or bond is a carbamate, ether, or acetal. Preferred prodrugs include but not limited to prodrugs having the structure nitroimidazole-(CH₂)_n-X, where n is 1 to 5, preferably 1, and X is OCO-anti-neoplastic agent, OCONH-anti-neoplastic agent, OCHOMe-anti-neoplastic agent, or O-anti-neoplastic agent
10 (the prodrugs of the invention can also include the linkers described in the reference Naylor *et al.*, 1992, *J. Med. Chem.* 35:3573-78).

[0040] Administration of the hypoxia-activated prodrugs of the invention for the treatment of cancer can be effected by any method that enables delivery of the prodrugs to the site of action, the hypoxic region of a tumor. Many cancer drugs are administered by intravenous
15 injection, and the present invention provides formulations of the compounds of the invention suitable for such administration, including not only ready-for-injection formulations but also lyophilized or concentrated formulations that must be rehydrated or diluted, respectively, prior to injection. In addition to these formulations, the present invention provides formulations suitable for administration by oral routes, intraduodenal routes, parenteral
20 injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion), topical, and rectal routes. Those of skill in the art will recognize that the prodrugs of the invention can be activated by bacteria in the gut. If such activation is not desired, then the practitioner may employ a route of administration or a formulation that results in absorption of the prodrug prior to its entry into the large intestine or colon. The actual route of
25 administration and corresponding formulation of the invention will depend on the type of cancer being treated, the prodrug selected for administration, the severity of the cancer, and the age, weight, and condition of the patient, among other factors.

[0041] In similar fashion, the amount of the prodrug administered, and thus the amount of the prodrug contained in the dose administered and the product comprising that dose, will be
30 dependent on the subject being treated, the severity of the cancer, localization of the cancer, the rate of administration, the disposition of the prodrug (e.g., solubility and cytotoxicity), the

cytotoxic agent released by the prodrug, and the discretion of the prescribing physician. However, an effective dosage is typically in the range of about 0.001 to about 100 mg per kg body weight, preferably about 1 to about 35 mg/kg/day, in single or divided doses. For a 70 kg human, this would amount to about 0.05 to about 7 g/day, preferably about 0.2 to about 2.5 g/day. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect; larger doses can also be divided into several small doses for administration throughout the day.

[0042] The anti-neoplastic prodrug composition may, for example, be in a form suitable for oral administration as a tablet, capsule, pill powder, sustained release formulation, solution, and suspension; for parenteral injection as a sterile solution, suspension or emulsion; for topical administration as an ointment or cream; and for rectal administration as a suppository. The anti-neoplastic prodrug composition may be in unit dosage forms suitable for single administration of precise dosages and will typically include a conventional pharmaceutical carrier or excipient.

[0043] Suitable pharmaceutical carriers include inert diluents or fillers, water and various organic solvents. The pharmaceutical compositions may, if desired, contain additional ingredients such as flavorings, binders, excipients, and the like. Thus for oral administration, tablets containing various excipients, such as citric acid may be employed together with various disintegrants, such as starch, alginic acid, and certain complex silicates, and with binding agents such as sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate, and talc can be used to prepare the tablet forms of formulations of the prodrugs of the present invention. Solid compositions of a similar type can be employed in soft and hard filled gelatin capsules. Preferred materials, therefore, include lactose or milk sugar and high molecular weight polyethylene glycols. When aqueous suspensions or elixirs are desired for oral administration, the prodrug therein may be combined with various sweetening or flavoring agents, coloring matters or dyes and, if desired, emulsifying agents or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin, or combinations thereof.

[0044] Exemplary parenteral administration forms include solutions or suspensions of the hypoxia-activated prodrug in sterile aqueous solutions, for example, aqueous propylene glycol or dextrose solutions. Such dosage forms can be suitably buffered, if desired.

5 [0045] Methods of preparing various pharmaceutical compositions with a specific amount of active prodrug are known, or will be apparent, to those skilled in this art in view of this disclosure. For examples, see Remington's Pharmaceutical Sciences, Mack Publishing Company, Easter, Pa., 15th Edition (1975).

10 [0046] The prodrugs and pharmaceutical compositions thereof of the present invention can be used in accordance with the methods of the invention to treat any type of cancer in a human or other mammal. Such cancers include but are not limited to leukemia, breast cancer, skin cancer, bone cancer, liver cancer, brain cancer, cancer of the larynx, gallbladder, pancreas, rectum, parathyroid, thyroid, adrenal, neural tissue, head and neck, stomach, bronchi, kidneys, basal cell carcinoma, squamous cell carcinoma of both ulcerating and papillary type, metastatic skin carcinoma, osteosarcoma, Ewing's sarcoma, veticulum cell
15 sarcoma, myeloma, giant cell tumor, small-cell lung tumor, gallstones, islet cell tumor, primary brain tumor, acute and chronic lymphocytic and granulocytic tumors, hairy-cell tumor, adenoma, hyperplasia, medullary carcinoma, pheochromocytoma, mucosal neuronms, intestinal ganglioneuromas, hyperplastic corneal nerve tumor, marfanoid habitus tumor, Wilm's tumor, seminoma, leiomyomater tumor, cervical dysplasia and in situ carcinoma,
20 neuroblastoma, retinoblastoma, soft tissue sarcoma, malignant carcinoid, topical skin lesion, mycosis fungoide, rhabdomyosarcoma, Kaposi's sarcoma, osteogenic and other sarcoma, malignant hypercalcemia, renal cell tumor, polycythemia vera, adenocarcinoma, glioblastoma multiforma, leukemias, lymphomas, malignant melanomas, and epidermoid carcinomas.

25 [0047] The prodrugs of the invention are of course especially effective against cancers containing significant areas of hypoxic tissue. Such cancers include but are not limited to lung cancer, especially non-small cell lung cancer, breast cancer, colon cancer, head and neck cancer, ovarian cancer, pancreatic cancer, and prostate cancer. Several of these cancers are discussed for illustrative purposes below. Those of skill in the art will appreciate that cancer
30 chemotherapy often involves the simultaneous or successive administration of a variety of anti-cancer agents, and as discussed further below, the prodrugs of the invention can be used

in combination therapies as provided by the methods of the present invention. Thus, in the description of illustrative cancers containing hypoxic regions amenable to treatment with the prodrugs of the invention, illustrative combination therapies provided by the present invention are also described.

5 [0048] Lung cancer affects more than 100,000 males and 50,000 females in the United States, most of whom die within 1 year of diagnosis, making it the leading cause of cancer death. Current protocols for the treatment of lung cancer involve the integration of chemotherapy with or without radiotherapy or surgery. The hypoxia-activated prodrugs of the invention, including those that release chemotherapeutic agents presently used to treat various
10 forms of lung cancer, can be used to treat lung cancer, for example, by replacing a non-hypoxia-activated form in the combination, and other prodrugs of the invention can be used in existing combination therapies. A variety of combination chemotherapy regimens have been reported for small cell lung cancer, including the combinations consisting of cyclophosphamide, doxorubicin and vincristine (CAV); etoposide and cisplatin (VP-16); and
15 cyclophosphamide, doxorubicin and VP-16 (CAVP-16). Modest survival benefits from combination chemotherapy (etoposide plus cisplatin) treatment have been reported for non-small cell lung cancer. Prodrug forms of each of the chemotherapeutic agents mentioned above are provided by the present invention.

[0049] Likewise, several different cytotoxic drugs have produced at least temporary
20 regression of ovarian cancer. The most active drugs in the treatment of ovarian have been alkylating agents, including cyclophosphamide, ifosfamide, melphalan, chlorambucil, thiotepa, cisplatin, and carboplatin. Current combination therapies for ovarian cancer includes cisplatin or carboplatin in combination with cyclophosphamide at 3- to 4-week intervals for six to eight cycles. The present invention provides prodrug forms of each of these agents, and
25 methods for treating ovarian cancer in which a prodrug of the invention is used in such combinations, either to replace an agent or in addition to the agent(s) currently used.

[0050] Cancer of the prostate is the most common malignancy in men in the United States and is the second most common cause of cancer death in men above age 55, and this cancer has been reported to consist primarily of hypoxic tissue. Several chemotherapy protocols
30 have been reported for use in late stage disease following relapse after hormonal treatment. Agents for the treatment of prostate cancer include estramustine phosphate, prednimustine,

and cisplatin, and prodrug forms of each of these agents is provided by the present invention, as well as methods for treating prostate cancer using such agents. Combination chemotherapy is also used to treat prostate cancer, including treatment with estramustine phosphate plus prednimustine and cisplatin, and 5-fluorouracil, melphalan, and hydroxyurea. The present invention provides prodrug forms of each of these agents, and methods for treating prostate cancer in which a prodrug of the invention is used in such combinations, either to replace an agent or in addition to the agent(s) currently used.

[0051] Cancer of the large bowel is the second most common cause of cancer death in the United States and is likewise a cancer characterized by hypoxic regions. While chemotherapy in patients with advanced colorectal cancer has proven to be of only marginal benefit, 5-fluorouracil is the most effective treatment for this disease. 5-Fluorouracil is useful alone or in combination with other drugs, but is associated with only a 15 to 20 percent likelihood of reducing measurable tumor masses by 50 percent or more. Thus, the hypoxia-activated prodrug form of 5-FU provided by the present invention, and the methods for treating colon cancer using that prodrug, offer significant therapeutic benefit and potential for meeting the unmet need for better treatment methods for this disease.

[0052] As the foregoing discussion illustrates, the present invention provides methods for treating cancer in a human or other mammalian subject, which methods comprise administering to the subject an effective amount of a hypoxia-activated prodrug of the invention in combination with an effective amount of a chemotherapeutic agent (or agents), an effective amount of radiotherapy, an appropriate surgery procedure, or a combination of such therapies. Anti-neoplastic agents useful in combination with one or more prodrugs of the invention for the treatment of cancer include but are not limited to busulfan, improsulfan, piposulfan, benzodepa, carboquone, 2-deoxy-D-glucose, lonidamine, meturedpa, uredepa, altretamine, imatinib, triethylenemelamine, triethylenephosphoramidate, triethylenethiophosphoramidate, trimethylolomelamine, chlorambucil, chlornaphazine, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard, carmustine, chlorozotocin, fotemustine, nimustine, ranimustine, dacarbazine, mannomustine, mitobronitol, mitolactol, pipobroman, aclacinomycins, actinomycin F(1), anthramycin, azaserine, bleomycin, cactinomycin, carubicin, carzinophilin, chromomycin, dactinomycin, daunorubicin, daunomycin, 6-diazo-5-oxo-1-norleucine, mycophenolic acid, nogalamycin,

olivomycin, peplomycin, plicamycin, porfiromycin, puromycin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin, denopterin, pteropterin, trimetrexate, fludarabine, 6-mercaptopurine, thiamiprine, thioguanine, ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, 5-fluorouracil, tegafur, L-asparaginase, pulmozyme, aceglatone, aldophosphamide glycoside, aminolevulinic acid, amsacrine, bestrabucil, bisantrene, carboplatin, defofamide, demecolcine, diaziquone, elformithine, elliptinium acetate, etoglucid, flutamide, gallium nitrate, hydroxyurea, interferon-alpha, interferon-beta, interferon-gamma, interleukin-2, lentinan, mitoguazone, mitoxantrone, mopidamol, nitracrine, pentostatin, phenamet, pirarubicin, podophyllinic acid, 2-ethylhydrazide, procarbazine, razoxane, sizofiran, spirogermanium, paclitaxel, tamoxifen, teniposide, tenuazonic acid, triaziquone, 2,2',2''-trichlorotriethylamine, urethan, vinblastine, and vincristine.


[0053] These and other aspects and embodiments of the invention will be apparent to those of skill in the art upon contemplation of the foregoing disclosure and the illustrative embodiments provided in the following examples and so within the scope of the following claims.

Example 1

Synthesis of Nitroimidazole-based Hypoxia Activator Moieties

[0054] This example illustrates methods for the synthesis of nitroimidazole-based, hypoxic activator moiety intermediates useful in methods of the invention for synthesizing prodrugs of the invention. In part A, an illustrative method for the synthesis of N(3)-methyl-2-nitro-4-methanol, a compound called herein "the nitroimidazole primary alcohol" from ethyl sarcosine hydrochloride is provided. Because prodrugs of the invention containing this hypoxic activator moiety may in some cells be activated even under normoxic conditions due to the attack on the primary carbon of the alcohol by glutathione-S-transferase or via a similar mechanism, and because further substitution of this carbon can reduce or eliminate such unwanted activation, the present invention also provides the novel intermediate compounds of the invention called herein "the nitroimidazole secondary alcohol" and "the nitroimidazole tertiary alcohol" as well as the novel methods of the invention for their synthesis in parts B and C, respectively.


[0055] Part A. Synthesis of the Nitroimidazole Primary Alcohol. The following scheme provides a method for the synthesis of the nitroimidazole primary alcohol (compound 2 in the scheme) from ethyl sarcosine. In this scheme, ethylsarcosine hydrochloride is first converted to ethyl-N-formyl-C-formyl sarcosine hydrochloride; a suitable method for such conversion is described in the reference Jones, 1949, *J. Am. Chem. Soc.* 71: 644, incorporated herein by reference. The latter compound is then converted to a compound called herein "the nitroimidazole ester" (compound 1 in the scheme); a suitable method for such conversion is described in the reference Asato *et al.*, 1972, *J. Med. Chem.* 15: 1086, incorporated herein by reference. Then, the nitroimidazole ester is converted to the nitroimidazole primary alcohol; a suitable method for such conversion is described in Parveen *et al.*, 1999, *Bioorg. Med. Chem. Lett.* 9: 2031, incorporated herein by reference.



All the examples shown below have the nitroimidazole moiety bearing a methyl group at the 1 position. This methyl group can alternatively be an alkyl group bearing steric hinderance. Such analogs would be useful in reducing the reactivity of the 2 nitro group toward two electron reduction *in vivo* by oxygen insensitive enzymes such as DT diaphorase. By reducing the ability of the prodrugs to be activated by oxygen insensitive enzymes, the selectivity to hypoxic tumors will be enhanced. Such hindered analogs can be synthesized by



using the scheme above and substituting the N methylglycine ester with a hindered N alkyl glycine ester such as N neopentyl glycine ester. Other hindered groups can be envisioned such as t butyl, cyclohexyl, cyclopentyl, isopropyl or any heteroatom substituted variant.

- 5 [0056] **Part B. Synthesis of the Nitroimidazole Secondary Alcohol.** As noted above, the present invention provides a novel compound, the nitroimidazole secondary alcohol, and methods for its synthesis. In three different illustrative methods, as shown in the schemes below, either the nitroimidazole ester (compound 1 in the scheme in part A and in the schemes below) or the nitroimidazole primary alcohol (compound 2 in in the scheme in part
- 10 A and in the schemes below) is converted to the nitroimidazole secondary alcohol using either Cerium reagents (second scheme below; see Takeda *et al.*, *Organic Syntheses*, Volume 76, page 228 *et seq.* and the references cited therein, incorporated herein by reference) or Titanium reagents (first and third schemes below (see Imwinkelried *et al.* *Organic Syntheses*, Volume CV 8, page 495 *et seq.*, and the references cited therein, incorporated herein by
- 15 reference).



[0057] **Part C. Synthesis of the Nitroimidazole Tertiary Alcohol.** As noted above, the present invention provides a novel compound, the nitroimidazole tertiary alcohol, and

The first system of musical notation for 'The Rose Tree' features a treble clef and a key signature of one flat (B-flat). The melody is written on a single staff. The notes are: G4 (quarter), A4 (quarter), Bb4 (quarter), A4 (quarter), G4 (quarter), F4 (quarter), E4 (quarter), D4 (half). The lyrics 'The Rose Tree' are written below the staff, aligned with the notes: 'The' under G, 'Rose' under A, 'Tree' under Bb, and 'The' under A. The word 'The' is also written below the final D note.



CN1C=CC(=N1)[C@@H](O)R

D R = H
E R = Me

5

[0061] However, Compounds A, B, and C, above, should be less susceptible to glutathione/glutathione transferase mediated attack, due to the presence of a tertiary, as opposed to the primary (Compound D) or secondary (Compound E), alcohol in those compounds.

10


Prodrugs of Doxorubicin and Related Compounds

[0062] This Example describes illustrative prodrugs of the invention that release highly cytotoxic derivatives of doxorubicin. Those of skill in the art will appreciate that doxorubicin, epirubicin, and daunomycin, and the numerous analogs and derivatives of those compounds that have been and continue to be synthesized represent a class of compounds that can be readily converted into prodrugs of the invention based on the teachings herein. This example illustrates such prodrugs of the invention that release highly cytotoxic compounds under hypoxic conditions. Highly cytotoxic daunomycin derivatives are described in the reference Bakina and Farquhar, 1999, *Anti-cancer Drug Design* 14: 507, incorporated herein by reference. Part A of this Example illustrates a prodrug of the invention that releases such a highly cytotoxic derivative, referred to herein as a doxorubicin derivative, and that comprises


20

[0063] Part A. Hypoxia-activated Doxorubicin Derivative Prodrug. The single free amino group of doxorubicin, daunomycin, epirubicin, and derivatives thereof having only this single free amino group can be readily modified with the hypoxia-activated moieties of the the invention to yield prodrugs of the invention having the following structure (DOX is doxorubicin or one of the related compounds previously mentioned other than the free amino group):


[0063] Part A. Hypoxia-activated Doxorubicin Derivative Prodrug. The single free amino group of doxorubicin, daunomycin, epirubicin, and derivatives thereof having only this single free amino group can be readily modified with the hypoxia-activated moieties of the the invention to yield prodrugs of the invention having the following structure (DOX is doxorubicin or one of the related compounds previously mentioned other than the free amino group):




Under hypoxic conditions, the hypoxia-activated moiety is removed, releasing the following highly cytotoxic compound shown as iminium DOX (or Super Dox), below.



The prodrug of the invention can be made by the following scheme.



[0065] Part C. Hypoxia-activated Doxorubicin Diamine Derivative Prodrug. Doxorubicin can be derivatized in accordance with a synthetic method of the invention with an aminoethyl moiety to generate a dicationic doxorubicin derivative that is highly cytotoxic and binds more tightly to DNA than doxorubicin. The prodrug, the cytotoxic derivative released by the
 5 prodrug, and the method of synthesis of the prodrug are thus embodiments of the present invention. The prodrug of the invention has the following structure (in the structure below, X represents any of the diverse moieties present in doxorubicin, daunomycin, epirubicin, and their naturally occurring and synthetic derivatives):




10

[0066] Upon hypoxia-activated release, the compound is protonated to convert the carboxamates to the corresponding amines. The prodrug is formed by reacting doxorubicin or a doxorubicin derivative with $\text{HC(O)CH}_2\text{NHCO}_2\text{R}$, where R is defined as above, first in the presence of $\text{NaB(OAc)}_3\text{H}$ and then in the presence of $\text{R}'\text{CO}_2\text{Cl}$, where R' is C_{1-6} lower alkyl, and base.
 15


Example 3Prodrugs of Etoposide


[0067] Etoposide is a potent non-intercalating DNA topoisomerase II inhibitor. In accordance with the synthetic methods of the invention, one can readily form prodrugs of the invention that release etoposide under hypoxic conditions as follows. The hypoxia-activated moiety is attached to the etoposide at the phenolic hydroxy positions via an ether linker.

[0068] These linkers can be provided by other useful intermediate reagents of the invention, shown below. These reagents can be readily prepared from the corresponding alcohol



[0069] Two illustrative prodrugs, labeled A and B below, and a scheme for forming them from etoposide are shown below.






Example 4

Prodrugs of Vinca Alkaloids

- 5 [0070] Prodrugs of the invention that release vinblastine (or another vinca alkaloid) can be prepared from vinblastine (or another vinca alkaloid) as shown in the scheme below (the indole NH can be attached to the hypoxia-activated moiety selectively over attachment at the hydroxyls) using synthetic methodology substantially similar to that described in Example 3.




- 10 Vincristine-releasing prodrugs of the invention are prepared in an analogous manner, starting with vincristine.

Example 5

Prodrugs of Topotecan


- 15 [0071] Prodrugs of the invention that release topotecan can be prepared from topotecan as shown in the scheme below using synthetic methodology substantially similar to that described in Example 3.




Example 6

Prodrugs of Taxanes


- 5 [0072] Prodrugs of the invention that release paclitaxel, docetaxel, or another taxane can be prepared from paclitaxel (or docetaxel or another taxane) using synthetic methodology substantially similar to that described in Example 3 to prepare compounds similar in structure to the structure shown below.



- 10 [0073] As indicated in the structure above, such prodrugs of the invention can have one, two, three, or four hypoxia-activated moieties. In some embodiments, these hypoxia-activated moieties are selected from those shown below.




R = OCH₂Cl,



Example 7

Prodrugs of 5-FU

- 5 [0074] Prodrugs of the invention that release 5-fluorouracil (5-FU) can be prepared from 5-FU using synthetic methodology substantially similar to that described in Example 3. One such prodrug has the structure shown below.




- 10 Another prodrug of the invention has two hypoxia-activated moieties attached, one as shown in the structure above, and the other to the other ring nitrogen.

Example 8

Prodrugs of Alkylating Agents




- 15 [0075] Prodrugs of the invention that release an alkylating agent can be prepared from as shown in the scheme below using synthetic methodology substantially similar to that described in Example 3. A prodrug of cyclophosphamide provided by the invention is used to illustrate this aspect of the invention. This prodrug of the invention can be synthesized in accordance with the methods of the invention using the following illustrative synthetic method.



Example 9

Prodrugs of Hydroxyurea




- 5 [0076] Prodrugs of the invention that release hydroxyurea (HU) can be prepared from hydroxyurea as shown in the scheme below using synthetic methodology substantially similar to that described in Example 3. HU (sold as Hydrea by Bristol-Myers Squibb) is an anti-leukemic drug with a mechanism of action ascribed to the inhibition of the DNA synthesizing enzyme ribonucleoside reductase. HU has also been shown to be effective against brain
10 tumors (meningioma).



Example 10

Nitroimidazole-20-Camptothecin prodrugs

- 5 [0077] A representative example of a method of the invention for preparing an illustrative camptothecin prodrug of the invention is shown below.



Hypoxic triggered prodrug

[0078] The N methylacetate moiety on the imidazole can be synthesized by demethylating the hydroxymethyl imidazole derivative with hydroiodic acid and realkylating it with methyl bromoacetate. Upon prodrug formation, the methoxy ester is removed, optionally with sodium hydroxide followed by acid treatment to restore the active lactone of camptothecin.


[0079] Alternatively, the camptothecin lactone can be hydrolyzed to the open form and the alcohol moiety derivatized with a chloromethyl nitroimidazole or chloromethoxymethyl nitroimidazole derivative. This nitroimidazole derivative need not bear a carboxylic acid group off of the 1 position on the imidazole but can be rendered stable to two electron reduction by DT diaphorase by having a sterically hindered alkyl group, as discussed above. This reaction can be carried out by the bis alkylation of the free carboxylic acid and the alcohol followed by basic hydrolysis of the ester, leaving a free acid for solubility and the nitroimidazole prodrug moiety masking the essential alcohol functionality. Prodrug release under hypoxic conditions *in vivo* will result in the release of the alcohol. Subsequent cyclization with the carboxylic acid under the acidic conditions of the tumor will generate an active camptothecin. Such analogs of camptothecin provided by the invention can be prepared analogously, using any of the numerous camptothecin analogs known in the art as the drug to be formed from the prodrug of the invention.

Example 11

Nitroimidazole Prodrugs of Duocarmycin

[0080] Many duocarmycin analogs and their prodrugs are known (see U.S. patent No. 5,985,909, PCT patent publication No. US02/17210, and U.S. patent application publication No. 2003/0050331 A1). None of these analogs or prodrugs employ a nitroimidazole

triggered to release the duocarmycin using a stable ether connection to the phenolic group of the duocarmycin as provided by the present invention. A representative example of a nitroimidazole duocarmycin prodrug of the invention is shown below, the key feature of all of these duocarmycin prodrugs of the invention being protection of the phenolic oxygen as an ether with the nitroimidazole as shown. The synthesis starts, in one embodiment, with the free duocarmycin phenol and the nitroimidazole derivative bearing a bromomethyl or chloromethyl group as the precursor to the ether connection. R_1 can be H, methyl or lower alkyl, R_2 can be COOR, CN or NO_2 , X can be Cl, Br, I or sulfonate, R_3 and R_4 can be as described in PCT/US02/17210. The R_5 group on the nitroimidazole can be methyl or a hindered alkyl as described above.



[0081] The invention, having been described in summary and detail and illustrated by example, is set forth in the following claims.

[0082] All references cited herein are incorporated by reference.

What is claimed is:

1 1. A method for treating cancer in a subject, said method comprising
2 administering to said subject an effective amount of a hypoxia-activated prodrug, wherein
3 said hypoxia-activated prodrug has the formula:

4

5

Hyp-L-N

6

wherein

7

Hyp is a hypoxic activator;

8

L is a bond or a linking group; and

9

N is an anti-neoplastic agent.

1

2

2. A method in accordance with claim 1, wherein said hypoxic activator is
nitroimidazole.

1

2

3. A method in accordance with claim 2, wherein said hypoxic activator
comprises of two or more nitroazole moieties.

1

2

4. A method in accordance with claim 2, wherein said linking group is a
carbamate.

1

2

5. A method in accordance with claim 2, wherein said anti-neoplastic agent
has an average IC₅₀ against the NCI cancer cell line panel of less than 10 nM.

1

6. The method of Claim 5, wherein said IC₅₀ is less than 100 pM.

ABSTRACT OF THE INVENTION

[0083] Hypoxia-activated prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agent(s).

PA 3300455 v1